Skip to main content
OpenTrials
Completed

NCT Number: NCT02127580

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve

There is limited experience for the balloon expandable THV (transcatheter heart valve) on the need for predilation (ballon aortic valvuloplasty, BAV). Therefore we aim to verify results of a small case series published by Wendler et. al. to examine hard endpoints such as the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a multicenter registry.

We aim to compare the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinic for Cardiac Surgery Karlsruhe, Karlsruhe, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst >180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as:

  • Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia.
  • In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality.
  • BAV has been identified as a major source of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke.
  • The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with an indication for TAVI as to the Edwards THV IFU
  • Eligible for TABI with AND without BAV
  • Signed informed consent

Exclusion criteria

  • Logistic EuroSCORE I >50%
  • Mitral or tricuspid valvular insufficiency (> grade II)
  • Previous aortic valve replacement
  • Uncontrolled atrial fibrillation
  • Left ventricular or atrial thrombus by echocardiography
  • Recent cerebrovascular event (within the last 3 months)
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)

Treatment and study plan

BAV

Procedure

without BAV

Procedure

Primary outcomes

  1. VARC2 criteria

    Time frame: 3 months

    comparison of the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Sponsors and collaborators

Lead sponsor

Institut für Pharmakologie und Präventive Medizin

Network

Registry information

Official study title

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry

Acronym: EASE-IT

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Apr 30, 2014
Registry last updated
Apr 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.